" class="no-js "lang="en-US"> CTI BioPharma - Medtech Alert
Friday, March 29, 2024
CTI BioPharma | Pharmtech Focus

CTI BioPharma

About CTI BioPharma

CTI BioPharma

We are a Seattle based biopharmaceutical company focused on the development and commercialization of novel therapies that address unique unmet medical needs for patients suffering from blood-related cancers. Pacritinib, our lead product candidate is in development for the treatment of myelofibrosis which has the potential to fulfill a significant treatment gap in the management of these patients due to it’s unique clinical profile.

Related Story

Sobi to Acquire CTI BioPharma

May 10 2023

CTI BioPharma, a commercial biopharmaceutical company focused on the development and commercialization of novel targeted […]

CTI BioPharma Announces Topline Data from Final Analysis of the PRE-VENT Clinical Trial Evaluating Pacritinib as a Treatment for Severe COVID-19

October 4 2021

CTI BioPharma Corp. (Nasdaq: CTIC) today announced topline results from the PRE-VENT trial (NCT04404361) of pacritinib […]